In Oct 2007, the FDA announced which the labeling for all PDE5 inhibitors, which include tadalafil, requires a extra well known warning on the potential possibility of sudden Listening to reduction as the results of publish-marketing reviews of short term deafness related to usage of PDE5 inhibitors.[19][8] The FDA concluded that they ended up unab